Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.

Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, Wilkinson G, Wilson Z, Wood CM, Jewsbury PJ.

J Med Chem. 2018 Nov 10. doi: 10.1021/acs.jmedchem.8b01187. [Epub ahead of print]

PMID:
30346772
2.

Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.

Martin EC, Aarons L, Yates JWT.

Cancer Chemother Pharmacol. 2018 Oct;82(4):669-675. doi: 10.1007/s00280-018-3630-8. Epub 2018 Jul 27.

3.

Complete Substrate Inhibition of Cytochrome P450 2C8 by AZD9496, an Oral Selective Estrogen Receptor Degrader.

Bapiro TE, Sykes A, Martin S, Davies M, Yates JWT, Hoch M, Rollison HE, Jones B.

Drug Metab Dispos. 2018 Sep;46(9):1268-1276. doi: 10.1124/dmd.118.081539. Epub 2018 Jun 19.

PMID:
29921707
4.

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI.

Mol Cancer Ther. 2018 Aug;17(8):1670-1682. doi: 10.1158/1535-7163.MCT-18-0010. Epub 2018 Jun 11.

PMID:
29891488
5.

Outside-In Systems Pharmacology Combines Innovative Computational Methods With High-Throughput Whole Vertebrate Studies.

Schulthess P, van Wijk RC, Krekels EHJ, Yates JWT, Spaink HP, van der Graaf PH.

CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):285-287. doi: 10.1002/psp4.12297. Epub 2018 Apr 25.

6.

Understanding Hematological Toxicities Using Mathematical Modeling.

Fornari C, O'Connor LO, Yates JWT, Cheung SYA, Jodrell DI, Mettetal JT, Collins TA.

Clin Pharmacol Ther. 2018 Oct;104(4):644-654. doi: 10.1002/cpt.1080. Epub 2018 May 1. Review.

PMID:
29604045
7.

Structural identifiability for mathematical pharmacology: models of myelosuppression.

Evans ND, Cheung SYA, Yates JWT.

J Pharmacokinet Pharmacodyn. 2018 Feb;45(1):79-90. doi: 10.1007/s10928-018-9569-x. Epub 2018 Feb 2.

PMID:
29396780
8.

Arm crank ergometry improves cardiovascular disease risk factors and community mobility independent of body composition in high motor complete spinal cord injury.

Bresnahan JJ, Farkas GJ, Clasey JL, Yates JW, Gater DR.

J Spinal Cord Med. 2018 Jan 15:1-21. doi: 10.1080/10790268.2017.1412562. [Epub ahead of print]

PMID:
29334345
9.

Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identification.

Martin EC, Yates JWT, Ogungbenro K, Aarons L.

J Pharm Pharmacol. 2017 Oct;69(10):1275-1283. doi: 10.1111/jphp.12759. Epub 2017 Jun 27.

PMID:
28653461
10.

Erratum to: Multiscalar cellular automaton simulates in-vivo tumour-stroma patterns calibrated from in-vitro assay data.

Delgado-SanMartin JA, Hare JI, Davies EJ, Yates JWT.

BMC Med Inform Decis Mak. 2017 Jun 23;17(1):88. doi: 10.1186/s12911-017-0492-7. No abstract available.

11.

Multiscalar cellular automaton simulates in-vivo tumour-stroma patterns calibrated from in-vitro assay data.

Delgado-SanMartin JA, Hare JI, Davies EJ, Yates JWT.

BMC Med Inform Decis Mak. 2017 May 30;17(1):70. doi: 10.1186/s12911-017-0461-1. Erratum in: BMC Med Inform Decis Mak. 2017 Jun 23;17 (1):88.

12.

A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055.

Yates JWT, Holt SV, Logie A, Payne K, Woods K, Wilkinson RW, Davies BR, Guichard SM.

Br J Pharmacol. 2017 Aug;174(16):2652-2661. doi: 10.1111/bph.13886. Epub 2017 Jul 6.

13.

Characterization of Cancer Patients in Inpatient Rehabilitation Facilities: A Retrospective Cohort Study.

Mix JM, Granger CV, LaMonte MJ, Niewczyk P, DiVita MA, Goldstein R, Yates JW, Freudenheim JL.

Arch Phys Med Rehabil. 2017 May;98(5):971-980. doi: 10.1016/j.apmr.2016.12.023. Epub 2017 Feb 1.

14.

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.

Yates JW, Ashton S, Cross D, Mellor MJ, Powell SJ, Ballard P.

Mol Cancer Ther. 2016 Oct;15(10):2378-2387. Epub 2016 Jul 20.

15.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D.

Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. Epub 2016 Jul 19.

16.

Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals.

Martin EC, Aarons L, Yates JW.

Cancer Chemother Pharmacol. 2016 Jul;78(1):131-41. doi: 10.1007/s00280-016-3059-x. Epub 2016 May 25.

17.

Development of 1RM Prediction Equations for Bench Press in Moderately Trained Men.

Macht JW, Abel MG, Mullineaux DR, Yates JW.

J Strength Cond Res. 2016 Oct;30(10):2901-6. doi: 10.1519/JSC.0000000000001385.

PMID:
26913865
18.

Effects of Lumbosacral Manipulation on Isokinetic Strength of the Knee Extensors and Flexors in Healthy Subjects: A Randomized, Controlled, Single-Blind Crossover Trial.

Sanders GD, Nitz AJ, Abel MG, Symons TB, Shapiro R, Black WS, Yates JW.

J Chiropr Med. 2015 Dec;14(4):240-8. doi: 10.1016/j.jcm.2015.08.002. Epub 2015 Nov 6.

19.

Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression.

Martin EC, Aarons L, Yates JW.

Toxicol Sci. 2016 Mar;150(1):109-16. doi: 10.1093/toxsci/kfv316. Epub 2015 Dec 16.

20.

Oxygen-Driven Tumour Growth Model: A Pathology-Relevant Mathematical Approach.

Delgado-SanMartin JA, Hare JI, de Moura AP, Yates JW.

PLoS Comput Biol. 2015 Oct 30;11(10):e1004550. doi: 10.1371/journal.pcbi.1004550. eCollection 2015 Oct.

21.

Systems toxicology: modelling biomarkers of glutathione homeostasis and paracetamol metabolism.

Stahl SH, Yates JW, Nicholls AW, Kenna JG, Coen M, Ortega F, Nicholson JK, Wilson ID.

Drug Discov Today Technol. 2015 Aug;15:9-14. doi: 10.1016/j.ddtec.2015.06.003. Epub 2015 Jul 16. Review.

22.

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.

Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.

Mol Cancer Ther. 2015 Nov;14(11):2508-18. doi: 10.1158/1535-7163.MCT-15-0365. Epub 2015 Sep 10.

23.

Relationship of Physical Fitness Measures vs. Occupational Physical Ability in Campus Law Enforcement Officers.

Beck AQ, Clasey JL, Yates JW, Koebke NC, Palmer TG, Abel MG.

J Strength Cond Res. 2015 Aug;29(8):2340-50. doi: 10.1519/JSC.0000000000000863.

PMID:
26203741
24.

Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.

Yates JW, Dudley P, Cheng J, D'Cruz C, Davies BR.

Cancer Chemother Pharmacol. 2015 Aug;76(2):343-56. doi: 10.1007/s00280-015-2795-7. Epub 2015 Jun 20.

PMID:
26092323
25.

Tumour stromal morphology impacts nanomedicine cytotoxicity in patient-derived xenografts.

Delgado San Martin JA, Hare JI, Yates JW, Barry ST.

Nanomedicine. 2015 Jul;11(5):1247-52. doi: 10.1016/j.nano.2015.02.007. Epub 2015 Mar 6.

PMID:
25752857
26.

Non-invasive 3D time-of-flight imaging technique for tumour volume assessment in subcutaneous models.

Delgado San Martin JA, Worthington P, Yates JW.

Lab Anim. 2015 Apr;49(2):168-71. doi: 10.1177/0023677214562653. Epub 2014 Dec 5.

PMID:
25480658
27.

Experimental and mathematical analysis of in vitro Pitavastatin hepatic uptake across species.

Grandjean TR, Chappell MJ, Lench AM, Yates JW, O'Donnell CJ.

Xenobiotica. 2014 Nov;44(11):961-74. doi: 10.3109/00498254.2014.923952. Epub 2014 Jul 16.

PMID:
25028049
28.

Multiple myeloma in the very old: an IASIA conference report.

Tuchman SA, Shapiro GR, Ershler WB, Badros A, Cohen HJ, Dispenzieri A, Flores IQ, Kanapuru B, Jurivich D, Longo DL, Nourbakhsh A, Palumbo A, Walston J, Yates JW.

J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju067. doi: 10.1093/jnci/dju067.

29.

Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis.

Newham P, Ross D, Ceuppens P, Das S, Yates JW, Betts C, Reens J, Randall KJ, Knight R, McKay JS.

Inflamm Res. 2014 Feb;63(2):149-60. doi: 10.1007/s00011-013-0683-3. Epub 2013 Nov 17.

PMID:
24240228
30.

Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts.

Evans ND, Dimelow RJ, Yates JW.

Comput Methods Programs Biomed. 2014 May;114(3):e3-13. doi: 10.1016/j.cmpb.2013.06.014. Epub 2013 Aug 12.

PMID:
23948442
31.

Structural identifiability analyses of candidate models for in vitro Pitavastatin hepatic uptake.

Grandjean TR, Chappell MJ, Yates JW, Evans ND.

Comput Methods Programs Biomed. 2014 May;114(3):e60-9. doi: 10.1016/j.cmpb.2013.06.013. Epub 2013 Jul 17.

PMID:
23870173
32.

Model-based drug discovery: implementation and impact.

Visser SA, Aurell M, Jones RD, Schuck VJ, Egnell AC, Peters SA, Brynne L, Yates JW, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U.

Drug Discov Today. 2013 Aug;18(15-16):764-75. doi: 10.1016/j.drudis.2013.05.012. Epub 2013 May 29. Review.

PMID:
23726890
33.

Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR.

Cancer. 2013 Aug 1;119(15):2720-7. doi: 10.1002/cncr.28129. Epub 2013 Apr 30.

34.
35.

Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human.

Parkinson J, Visser SA, Jarvis P, Pollard C, Valentin JP, Yates JW, Ewart L.

J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):357-66. doi: 10.1016/j.vascn.2013.03.007. Epub 2013 Apr 6.

PMID:
23567074
36.

The design and analysis of parallel experiments to produce structurally identifiable models.

Cheung SY, Yates JW, Aarons L.

J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):93-100. doi: 10.1007/s10928-012-9291-z. Epub 2013 Jan 9.

PMID:
23300030
37.

Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis.

Yates JW, Das S, Mainwaring G, Kemp J.

J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):591-9. doi: 10.1007/s10928-012-9270-4. Epub 2012 Sep 23.

PMID:
23001587
38.

Long-term survival of older breast cancer patients: population-based estimates over three decades.

Kanapuru B, Ershler WB, Hesdorffer C, Jemal A, Yates JW.

Breast Cancer Res Treat. 2012 Jul;134(2):853-7. doi: 10.1007/s10549-012-2115-4. Epub 2012 Jun 19.

PMID:
22710707
39.

The effect of fatigue and training status on firefighter performance.

Dennison KJ, Mullineaux DR, Yates JW, Abel MG.

J Strength Cond Res. 2012 Apr;26(4):1101-9. doi: 10.1519/JSC.0b013e31822dd027.

PMID:
22446677
40.

Structural identifiability analysis and reparameterisation (parameter reduction) of a cardiovascular feedback model.

Cheung SY, Majid O, Yates JW, Aarons L.

Eur J Pharm Sci. 2012 Jul 16;46(4):259-71. doi: 10.1016/j.ejps.2011.12.017. Epub 2012 Feb 16.

PMID:
22343490
41.

Who needs a bag?

Gladden LB, Yates JW, Howley ET.

Med Sci Sports Exerc. 2012 Feb;44(2):288-9. doi: 10.1249/MSS.0b013e3182376b93. No abstract available.

PMID:
22251923
42.

Estimating insulin sensitivity from glucose levels only: Use of a non-linear mixed effects approach and maximum a posteriori (MAP) estimation.

Yates JW, Watson EM.

Comput Methods Programs Biomed. 2013 Feb;109(2):134-43. doi: 10.1016/j.cmpb.2011.12.014. Epub 2012 Jan 12.

PMID:
22244505
43.

Opinion on opinions about geriatric assessment.

Yates JW, Thein M, Ershler WB.

Arch Gerontol Geriatr. 2012 Mar-Apr;54(2):273-7. doi: 10.1016/j.archger.2011.07.007. Epub 2011 Oct 5. No abstract available.

PMID:
21978413
44.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4090-110. doi: 10.1002/jps.22552. Epub 2011 May 3.

PMID:
21541938
45.

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Yates JW.

J Pharm Sci. 2011 Oct;100(10):4127-57. doi: 10.1002/jps.22550. Epub 2011 May 3.

PMID:
21541937
46.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.

Poulin P, Jones HM, Jones RD, Yates JW, Gibson CR, Chien JY, Ring BJ, Adkison KK, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Ku MS.

J Pharm Sci. 2011 Oct;100(10):4050-73. doi: 10.1002/jps.22554. Epub 2011 Apr 26.

PMID:
21523782
47.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.

Vuppugalla R, Marathe P, He H, Jones RD, Yates JW, Jones HM, Gibson CR, Chien JY, Ring BJ, Adkison KK, Ku MS, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4111-26. doi: 10.1002/jps.22551. Epub 2011 Apr 7.

PMID:
21480234
48.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.

Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4074-89. doi: 10.1002/jps.22553. Epub 2011 Mar 30.

PMID:
21452299
49.

Assessment of accuracy of the Vacu-Med 17053 calibrator for ventilation, oxygen uptake (V(O(2))), and carbon dioxide production (V(CO(2))).

Bunn JA, Pittsley JL, Baker SV, Yates J.

Respir Care. 2011 Apr;56(4):472-6. doi: 10.4187/respcare.00951. Epub 2011 Jan 21.

50.

A new general glucose homeostatic model using a proportional-integral-derivative controller.

Watson EM, Chappell MJ, Ducrozet F, Poucher SM, Yates JW.

Comput Methods Programs Biomed. 2011 May;102(2):119-29. doi: 10.1016/j.cmpb.2010.08.013. Epub 2010 Dec 16.

PMID:
21163548

Supplemental Content

Loading ...
Support Center